RT Journal Article
SR Electronic
T1 Evidence from human placenta, ER-stressed trophoblasts and transgenic mice links transthyretin proteinopathy to preeclampsia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.12.22269156
DO 10.1101/2022.01.12.22269156
A1 Shibin Cheng
A1 Zheping Huang
A1 Sayani Banerjee
A1 Joel N. Buxbaum
A1 Surendra Sharma
YR 2022
UL http://medrxiv.org/content/early/2022/01/13/2022.01.12.22269156.abstract
AB We have demonstrated that protein aggregation plays a pivotal role in the pathophysiology of preeclampsia (PE) and identified several aggregated proteins in the circulation of PE patients, most significantly the serum protein transthyretin (TTR). Here we show robust accumulation of TTR aggregates in the placentas of women with early-onset PE (e-PE). TTR aggregation was inducible in primary human trophoblasts (PHTs) and the TCL-1 trophoblast cell line by ER stress inducers or autophagy-lysosomal disruptors. Hypoxia/reoxygenation (H/R) of cultured PHTs increased intracellular BiP, phosphorylated IRE1α, PDI and Ero-1, all markers of the UPR, and the apoptosis mediator caspase-3. Blockade of IRE1α inhibited H/R-induced upregulation of Ero-1 in PHTs. Excessive UPR was observed in the PE placenta. Further, pregnant mice, overexpressing transgene encoded wild type human TTR, displayed aggregated TTR in the junctional zone of the placenta and PE-like features including hypertension, proteinuria, intrauterine growth restriction, kidney injury, and elevated levels of the PE biomarkers serum sFlt-1 and endoglin. High Resolution Ultrasound analysis revealed low blood flow in uterine and umbilical arteries compared to that found in wild type pregnant mice. On the other hand, loss of mouse TTR function did not cause any pregnancy abnormalities in Ttr-/- mice. These observations in the PE placenta, cultured trophoblast cells and TTR transgenic mice indicate that TTR aggregation is an important causal contributor to PE pathophysiology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the NIH P20 GM121298, P30 GM114750, 3P20GM121298-04W1 grants and Brown University Seed Award (SS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Women and Infants Hospital IRB committee gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are included in the manuscript.EREndoplasmic reticulumBiPBinding immunoglobulin proteinEro1endoplasmic reticulum oxidoreductin 1IRE1αInositol-requiring enzyme-1αLAMP1lysosome-associated membrane protein 1PDIprotein disulfide isomerasepIRE1αPhosphorylated inositol-requiring enzyme-1αsEngsoluble endoglinsFlt-1soluble fms-like tyrosine kinase-1TTRtransthyretinUPRunfolded protein response